4D Molecular Therapeutics
FDMT
125 hedge funds and large institutions have $141M invested in 4D Molecular Therapeutics in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 59 reducing their positions, and 37 closing their positions.
21% more call options, than puts
Call options by funds: $156K | Put options by funds: $129K
8.27% less ownership
Funds ownership: 101.33% → 93.06% (-8.3%)
14% less funds holding
Funds holding: 145 → 125 (-20)
46% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 59
46% less capital invested
Capital invested by funds: $262M → $141M (-$121M)
54% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$8.91M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.87M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$2.12M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.73M |
| 5 |
Two Sigma Advisers
New York
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$10.7M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$6.83M |
| 3 |
CC
Casdin Capital
New York
|
-$6.41M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$2.79M |
FDMT Hedge Fund Activity: Q1 2025 in Review
125 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2025, worth a combined $141M — down 46% from $262M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of FDMT and 17 opened new positions — a net loss of 20 holders — while 59 trimmed existing stakes and 32 added.
The largest buyer was BVF Inc, adding an estimated $8.91M. The largest seller was VR Adviser, cutting an estimated $10.7M.
- 125 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2025, down from 145 in Q4 2024.
- Funds reported $141M of 4D Molecular Therapeutics stock for Q1 2025, down 46% quarter-over-quarter.
- 17 funds opened new 4D Molecular Therapeutics positions in Q1 2025 and 37 closed out, a net change of -20 holders.
- The largest 4D Molecular Therapeutics buyer in Q1 2025 was BVF Inc, an estimated $8.91M added.
- The largest 4D Molecular Therapeutics seller in Q1 2025 was VR Adviser, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2025.